Gregory L. Verdine - Jun 13, 2025 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Role
Director
Signature
/s/ Gregory L. Verdine
Stock symbol
WVE
Transactions as of
Jun 13, 2025
Transactions value $
-$208,500
Form type
4
Date filed
6/13/2025, 08:00 PM
Previous filing
Mar 7, 2025
Next filing
Aug 13, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Verdine Gregory L. Director C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE /s/ Gregory L. Verdine 2025-06-13 0001572315

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WVE Ordinary Shares Sale -$209K -30K -9.6% $6.95 283K Jun 13, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.
F2 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.79 to $7.04 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.